Maxim Group reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note issued to investors on Wednesday. The firm currently has a $14.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also recently issued reports on ABEO. Zacks Investment Research cut Abeona Therapeutics from a hold rating to a sell rating in a report on Monday, July 4th. Cantor Fitzgerald reissued a buy rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, September 30th. FBR & Co set a $15.00 price target on Abeona Therapeutics and gave the stock a buy rating in a report on Thursday, August 18th. Finally, Rodman & Renshaw reissued a buy rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Sunday, August 21st. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $14.50.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.54 on Wednesday. Abeona Therapeutics has a one year low of $2.05 and a one year high of $7.19. The firm has a 50-day moving average price of $5.43 and a 200 day moving average price of $3.49. The stock’s market capitalization is $219.38 million.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. On average, equities analysts expect that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.
In other news, Director Todd Wider purchased 5,000 shares of the stock in a transaction on Tuesday, September 20th. The stock was purchased at an average price of $5.48 per share, with a total value of $27,400.00. Following the completion of the transaction, the director now owns 75,000 shares in the company, valued at $411,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 13.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Royce & Associates LP boosted its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC boosted its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares in the last quarter. Institutional investors own 19.95% of the company’s stock.
About Abeona Therapeutics